Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients

This study has been completed.
Information provided by:
Ipsen Identifier:
First received: September 19, 2005
Last updated: June 26, 2008
Last verified: June 2008
To evaluate the long-term efficacy and safety of repeated injections of lanreotide Autogel given in doses titrated to effect in acromegalic patients previously treated or not with somatostatin analogues.

Condition Intervention Phase
Drug: Lanreotide (Autogel formulation)
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase III, Multicentre, Open Study to Assess the Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients Previously Treated or Not by Somatostatin Analogues.

Resource links provided by NLM:

Further study details as provided by Ipsen:

Primary Outcome Measures:
  • Percentage of patients having a normal (age-adjusted) serum insulin-like growth factor 1 (IGF-1) level at end point (Week 48)

Secondary Outcome Measures:
  • Percentage of variation from baseline of the IGF-1 levels expressed as a percentage of the upper limit of the age-adjusted normal range
  • Mean growth hormone (GH) levels
  • Number of patients having a serum GH level at or below 2.5ng/ml
  • Number of patients having a serum GH level at or below 1 ng/ml
  • Number of patients with no or reduced clinical signs of acromegaly
  • Long-term safety of repeated injections of lanreotide autogel at titrated doses

Estimated Enrollment: 60
Study Start Date: September 2000

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient having documentation supporting diagnosis of active acromegaly in one of the following definitions:

    • patient having received neither somatostatin analogue nor dopaminergic agonist within the previous 12 weeks and having an IGF-1 level at least 1.3 times the upper limit of the age-adjusted normal range,
    • patient being treated with a somatostatin analogue (other than lanreotide autogel) or a dopaminergic agonist when attending the first visit and having at the end of the wash-out period an IGF-1 level at least 1.3 times the upper limit of the age-adjusted normal range.

Exclusion Criteria:

  • Patient having had pituitary surgery within the previous 3 months
  • Patient having received radiotherapy for acromegaly disease within the previous 36 months
  • Patient being predicted to require pituitary surgery (adenomectomy) or receive radiotherapy during the study period
  • Patient having received lanreotide autogel at any time before the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00210457

Hôpital Sud
Amiens, France, 80054
Chu d'Angers
Angers, France, 49033
Hôpital de Bois Guillaume
Bois Guillaume, France, 76233
Chu de la Cote de Nacre
Caen, France, 14033
Hôpital du Bocage
Dijon, France, 21034
Chu de Bicêtre
Le Kremlin Bicêtre, France, 94270
Hôpital du Cluzeau
Limoges, France, 87042
Hôpital Neurologique
Lyon, France, 69394
Hôpital Lapeyronie
Montpellier, France, 34059
Hôpital de l'Archet 1
Nice, France, 06202
Hôpital du Haut-Levêque
Pessac, France, 33604
Hôpital Maison Blanche
Reims, France, 51092
Hôpital Sud
Rennes, France, 35056
Hôpital Bellevue
St Etienne, France, 42055
Hôpital de Hautepierre
Strasbourg, France, 67098
Hôpital de Rangueil
Toulouse, France, 31403
Centre Hospitalier Vaudois
Lausanne, Switzerland, CH-1011
Sponsors and Collaborators
Study Director: Joelle Blumberg, MD Ipsen
  More Information

Publications: Identifier: NCT00210457     History of Changes
Other Study ID Numbers: E-54-52030-081 (311)
Study First Received: September 19, 2005
Last Updated: June 26, 2008

Additional relevant MeSH terms:
Bone Diseases, Endocrine
Bone Diseases
Musculoskeletal Diseases
Pituitary Diseases
Hypothalamic Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Endocrine System Diseases
Antineoplastic Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs processed this record on May 23, 2017